Anlotinib Plus Penpulimab

DRUG2 trials

Sponsors

Hunan Cancer Hospital

Conditions

Non Small Cell Lung CancerSmall Cell Lung Cancer

Phase 2

Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy

CompletedNCT05001971

Hunan Cancer HospitalSmall Cell Lung Cancer

Start: 2021-01-30End: 2025-04-15Updated: 2026-01-15

Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors

Hunan Cancer HospitalNon Small Cell Lung Cancer

Start: 2022-06-12End: 2024-12-31Target: 29Updated: 2022-07-20

Related Papers

Efficacy and biomarker exploration of anlotinib plus penpulimab in second-line ES-SCLC: Results from the phase 2 ALTER-L041 trial.

2026-07-22

The combination therapy of anlotinib and penpulimab for the treatment of small cell lung cancer after platinum-based chemotherapy: Results of a phase II exploratory study.

Journal of Clinical Oncology2023-06-01